Successful Dosing of Final Patient in ACHIEVE Safety Cohort of TCB008 Trial Announced February 8, 2023
TROPION-Lung07 Ph 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in 1L mNSCLC Patients February 8, 2023
First Patient Dosed in NMIBC Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy February 8, 2023
Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer Initiated February 8, 2023
Avutometinib + Defactinib Combination Advancing in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Based on Positive Data from Planned Interim Analysis of Part A of RAMP 201 Trial February 8, 2023
KEYNOTE-991 Trial Evaluating KEYTRUDA® Plus Enzalutamide and Androgen Deprivation Therapy in Patients With mHSPC to Stop for Futility February 1, 2023
First Patient dosed in Ph I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors February 1, 2023
First Patient Dosed in VIRAGE, a Ph 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma February 1, 2023
First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma February 1, 2023
Enrollment in Ph 1 Trial of ADXS-504 for the Treatment of Early Prostate cancer completed January 17, 2023
Enrollment in Ph 2 Clinical Trial MN-166 (ibudilast) trial in Recurrent and Newly Diagnosed Glioblastoma patients completed January 17, 2023
Enrollment Completed in the Global Registrational Ph 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer January 11, 2023
50% Enrollment completed in Randomised Ph IIb TACTI-003 Trial for 1L Head & Neck Cancer January 11, 2023
First Patient Dosed in Ph 2 PRESERVE-004 Trial of ONC-392 + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer January 11, 2023
Safety Review Committee Approves to Proceed to Final Cohort in Acclaim-1 Ph 1 Dose Escalation Trial of REQORSA® + Tagrisso® in Advanced NSCLC December 19, 2022
